Skip to main navigation
Skip to search
Skip to main content
University of Hertfordshire (Research Profiles) Home
Home
Profiles
Research output
Projects
Research units
Search by expertise, name or affiliation
Lowering the risk of stroke prevention: Managing bleeding complications
Diana Gorog
Basic and Clinical Science Unit
Centre for Health Services and Clinical Research
School of Life and Medical Sciences
Department of Clinical, Pharmaceutical and Biological Science
Research output
:
Contribution to journal
›
Editorial
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Lowering the risk of stroke prevention: Managing bleeding complications'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Stroke Risk
100%
Bleeding Complications
100%
Stroke Prevention
100%
Dabigatran
100%
Bleeding
87%
Reversal Agents
75%
Non-vitamin K Antagonist Oral Anticoagulants
62%
Anticoagulation
50%
Thromboprophylaxis
50%
Atrial Fibrillation
50%
Oral Anticoagulants
50%
Rivaroxaban
50%
Apixaban
50%
Idarucizumab
37%
Anticoagulant Effect
37%
Major Bleeding
37%
Intracranial Hemorrhage
37%
Oral Anticoagulation
37%
Life-threatening Bleeding
25%
Factor Xa Inhibitors
25%
Warfarin
25%
Andexanet Alfa
25%
Vitamin K Antagonists
25%
Anti-factor Xa
25%
Bleeding Risk
12%
Internist
12%
European Society of Cardiology
12%
Early Recognition
12%
European Medicines Agency
12%
Closed-loop
12%
FDA-approved Drugs
12%
Head-to-head Comparison
12%
Sequester
12%
Edoxaban
12%
Bleeding Rate
12%
Emergency Operation
12%
Pole Position
12%
Dialysis
12%
Venous Thromboembolism
12%
Optimal Strategy
12%
Barriers to Use
12%
Prothrombin Complex Concentrate
12%
Massive Hemorrhage
12%
Fresh Frozen Plasma
12%
Reversal Strategies
12%
Orphan Drugs
12%
Intracranial Bleeding
12%
Cardiologists
12%
Insurgency
12%
Anticoagulants
12%
Randomized Clinical Trial
12%
Aging Population
12%
Hospital Stay
12%
Retroperitoneal Hemorrhage
12%
Anticoagulation Reversal
12%
Humanized
12%
Optimal Treatment
12%
Position Paper
12%
Secondary Care
12%
Thrombosis
12%
Accelerated Approval
12%
Stroke Physician
12%
Systemic Embolism
12%
Gastrointestinal Hemorrhage
12%
Cardiovascular Pharmacotherapy
12%
Year 2018
12%
Tertiary Care
12%
Recombinant
12%
Life-threatening
12%
Healthy Volunteers
12%
Acid Activation
12%
Trauma
12%
Surgeons
12%
Preventing Stroke
12%
ACC Guidelines
12%
Tranexamic Acid
12%
Healthcare Professionals
12%
Development Validation
12%
Median Time
12%
Decoy
12%
Prescribers
12%
Activated Charcoal
12%
Perceived Barriers
12%
General Measure
12%
Oral Anticoagulant Therapy
12%
Effective Management
12%
Economic Incentives
12%
Patients at Risk
12%
New Agents
12%
Patient Identification
12%
Physician Care
12%
Potential Reversal
12%
Expert Consensus Decision Pathway
12%
Monoclonal Antibody Fragment
12%
Andexanet
12%
Fatal Bleeding
12%
Risk Scoring System
12%
Primary Care
12%
International Recommendations
12%
Number of Patients
12%
Phase II Study
12%
Anticoagulated Patients
12%
Factor Xa
12%
Primary Care Physicians
12%
Operative
12%
Perceived Risk
12%
Bleeding Events
12%
Medicine and Dentistry
Apoplexy
100%
Antithrombotic
100%
Bleeding
100%
Anticoagulation
61%
Dabigatran
61%
Thromboprophylaxis
30%
Cerebral Hemorrhage
30%
Atrial Fibrillation
30%
Rivaroxaban
30%
Apixaban
30%
Prothrombinase
23%
Major Bleeding
23%
Idarucizumab
23%
Vitamin K Antagonist
23%
Primary Health Care
15%
Warfarin
15%
Clinician
15%
Health Care Cost
15%
Andexanet Alfa
15%
Medicine
7%
Randomized Clinical Trial
7%
Gastrointestinal Bleeding
7%
Venous Thromboembolism
7%
Factor X
7%
Awareness
7%
Thrombosis
7%
Tertiary Care
7%
Scoring System
7%
Cardiology
7%
Reversal Potential
7%
Secondary Care
7%
Monoclonal Antibody
7%
Retroperitoneal Hemorrhage
7%
Orphan Drug
7%
Incentive
7%
Edoxaban
7%
Blood Clotting Factor 10a Inhibitor
7%
Surgeon
7%
Anticoagulant Therapy
7%
Drug Therapy
7%
Fresh Frozen Plasma
7%
Activated Charcoal
7%
Emergency Surgical Procedure
7%
Injury
7%
Cardiovascular System
7%
Tranexamic Acid
7%
Prothrombin
7%
Prothrombin Complex
7%
Volunteer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cerebrovascular Accident
100%
Anticoagulant Agent
100%
Bleeding
100%
Dabigatran
61%
Rivaroxaban
30%
Vitamin K Group
30%
Atrial Fibrillation
30%
Brain Hemorrhage
30%
Apixaban
30%
Antivitamin K
23%
Idarucizumab
23%
Blood Clotting Factor 10a
23%
Warfarin
15%
Andexanet Alfa
15%
Monoclonal Antibody
7%
Blood Clotting Factor 10
7%
Prothrombin Complex
7%
Normal Human
7%
Edoxaban
7%
Blood Clotting Factor 10a Inhibitor
7%
Fresh Frozen Plasma
7%
Thrombosis
7%
Randomized Clinical Trial
7%
Tranexamic Acid
7%
Retroperitoneal Hemorrhage
7%
Pharmacotherapy
7%
Injury
7%
Gastrointestinal Hemorrhage
7%
Venous Thromboembolism
7%
Activated Carbon
7%
Orphan Drug
7%
Prothrombin
7%